BioLineRx Ltd. (NASDAQ:BLRX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.

According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “

Other equities research analysts also recently issued reports about the stock. Maxim Group set a $3.00 price objective on shares of BioLineRx and gave the stock a “buy” rating in a research note on Monday, July 10th. HC Wainwright set a $4.00 target price on shares of BioLineRx and gave the stock a “buy” rating in a report on Saturday, June 3rd. Roth Capital set a $3.00 target price on shares of BioLineRx and gave the stock a “buy” rating in a report on Wednesday, August 9th. ValuEngine raised shares of BioLineRx from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Finally, Oppenheimer Holdings, Inc. initiated coverage on shares of BioLineRx in a report on Friday, August 4th. They set an “outperform” rating and a $3.00 target price for the company. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. BioLineRx currently has a consensus rating of “Buy” and an average target price of $2.59.

BioLineRx (NASDAQ BLRX) traded down 6.818% during midday trading on Tuesday, hitting $1.025. The stock had a trading volume of 616,246 shares. BioLineRx has a 52-week low of $0.80 and a 52-week high of $1.42. The firm has a 50-day moving average of $1.01 and a 200 day moving average of $0.98. The firm’s market capitalization is $98.01 million.

BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.05) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.05). On average, equities analysts forecast that BioLineRx will post ($0.24) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This story was first reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2017/08/22/biolinerx-ltd-blrx-upgraded-at-zacks-investment-research.html.

Several hedge funds and other institutional investors have recently modified their holdings of BLRX. Senvest Management LLC boosted its position in shares of BioLineRx by 0.6% in the fourth quarter. Senvest Management LLC now owns 3,603,300 shares of the biotechnology company’s stock valued at $4,684,000 after buying an additional 20,000 shares during the period. Menta Capital LLC boosted its position in shares of BioLineRx by 11.7% in the first quarter. Menta Capital LLC now owns 98,917 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 10,400 shares during the period. Alyeska Investment Group L.P. boosted its position in shares of BioLineRx by 0.8% in the fourth quarter. Alyeska Investment Group L.P. now owns 642,421 shares of the biotechnology company’s stock valued at $591,000 after buying an additional 5,118 shares during the period. Benchmark Capital Advisors boosted its position in shares of BioLineRx by 227.3% in the first quarter. Benchmark Capital Advisors now owns 144,000 shares of the biotechnology company’s stock valued at $138,000 after buying an additional 100,000 shares during the period. Finally, Citadel Advisors LLC boosted its position in shares of BioLineRx by 443.4% in the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 86,481 shares during the period. 34.98% of the stock is owned by hedge funds and other institutional investors.

About BioLineRx

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

Get a free copy of the Zacks research report on BioLineRx (BLRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for BioLineRx (NASDAQ:BLRX)

Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.